# E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

> **NCT00236197** · PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 619 (actual)

## Conditions studied

- Heartburn

## Interventions

- **DRUG:** rabeprazole sodium
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00236197
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-03
- **Final completion:** 2008-06
- **Target enrollment:** 619 (ACTUAL)
- **Last updated:** 2009-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00236197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00236197, "E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00236197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*